Tafamidis is an oral small molecule candidate that selectively binds at specific sites on the transthyretin tetramer to prevent destabilization of the transthyretin transport protein and formation of amyloid that causes ATTR-CM.
The HERCULES (NCT02553317) study included 145 patients with aTTP who were randomized to receive either caplacizumab 10mg or placebo in conjunction with plasma exchange and immunosuppression.
Vecuronium Bromide, a neuromuscular blocker, is indicated as adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Sandoz and Pear Therapeutics announced the launch of reSET-O, a new digital therapeutic for patients aged ≥18 years with opioid use disorder (OUD) currently under clinician care.
HeartGuide is designed as a wrist watch that uses the oscillometric cuff method, the standard for medical-grade personal blood pressure measurement.
There is currently no approved treatment for progeria, an ultra-rare and rapidly fatal genetic condition that causes accelerated aging in children.
Alprazolam was found to be the most commonly misused benzodiazepine.
ProAir Digihaler is the first digital inhaler with built-in sensors that connects to a mobile application and provides data on inhaler use to patients with asthma and chronic obstructive pulmonary disease (COPD).
reSET-O is intended for use as an adjunct to outpatient treatment that includes transmucosal buprenorphine (medication-assisted-treatment [MAT]) and contingency management for patients aged ≥18 years who are currently under clinician supervision.